+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

This trial focuses on elderly patients aged 80 years or older, or those 75 years and older who are considered frail, with untreated diffuse large B-cell lymphoma DLBCL and related lymphoma subtypes. The study is a phase III, randomized, open-label, multicenter trial conducted in several countries including Sweden, Norway, Finland, Denmark, Italy, Australia, and New Zealand. It aims to compare the standard chemotherapy regimen R-miniCHOP with an experimental treatment R-pola-miniCHP, where vincristine is replaced by polatuzumab vedotin, to assess differences in outcomes for this patient population. Participants will be randomly assigned to one of two treatment groups. One group will receive R-mini-CHOP consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone over six 21-day cycles. The other group will receive R-pola-mini-CHP, which includes rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin instead of vincristine, also given over six 21-day cycles. Both treatments last approximately 18 weeks. The study includes a screening period lasting up to 4 weeks before treatment begins. During the study, participants will be followed for up to 36 months after completing treatment to monitor progression-free survival over two years. Researchers will evaluate disease progression and safety outcomes through regular assessments during and after the treatment period. Participants will provide informed consent and undergo evaluations including health status and disease measurements to ensure eligibility and monitor treatment effects throughout the trial.

Age: 75Years +All GendersPhase 3
69 locations
F

Actively Recruiting

Researchers are evaluating the long-term effects of music therapy on people with substance use disorder SUD in this randomized clinical trial called FALCO. The study compares two types of music therapy interventionsactive music making and music listeningwith the usual treatment offered locally. This trial involves 600 participants from multiple European countries and aims to assess changes in addiction severity one year after starting the study. Participants are randomly assigned to one of three groups an Active Music Group AMG that involves playing music together, a Music Listening Group MLG that focuses on listening to music in groups, or a Treatment as Usual TAU group receiving the standard care available locally. Both music therapy groups meet weekly for sessions lasting up to 90 minutes, led by qualified music therapists. All participants continue to receive their local standard treatments alongside the study interventions. During the study, participants will undergo various assessments including addiction severity, substance use, recovery, quality of life, depressive symptoms, motivation, craving, social connectedness, cognitive and brain function, and more. These evaluations occur at baseline, 3 months, 1 year, and up to 10 years for some outcomes like employment and hospitalizations. Researchers also monitor safety and adverse effects. The study spans from 2025 to 2037, with primary outcome measurement at one year and long-term follow-up planned.

Age: 18Years +All GendersPhase Not Applicable
11 locations
N

Actively Recruiting

Researchers are conducting an observational study to understand how new immunotherapies are used in treating multiple myeloma and related conditions in Norway. The study aims to fill knowledge gaps, provide evidence for future trials, and help develop guidelines for monitoring and managing side effects to improve patient survival and quality of life. This research focuses on patients with multiple myeloma, primary plasma cell leukemia, and AL amyloidosis. Participants are observed while receiving immunotherapies including Teclistamab, Elranatamab, Talquetamab, Idecabtagene vicleucel, and Ciltacabtagene Autoleucel as part of their routine care outside of clinical trials. The study monitors how these treatments are used in real-world settings, including dosing and administration. There is no assigned treatment group or placebo instead, the study collects data on treatments given during regular healthcare. Throughout the study, participants response to treatment, progression-free survival, time to next treatment, overall survival, and adverse events are tracked for up to ten years. Researchers collect data on infections, antibiotic resistance, airway viruses, and use of antimicrobial prophylaxis during therapy. This long-term monitoring aims to provide comprehensive safety and effectiveness information to guide future care and research.

Age: 18Years +All Genders
23 locations